QC
NGNE icon

Quadrature Capital’s Neurogene NGNE Stock Holding History

Quadrature Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,828
Closed -$292K – 1533
2025
Q3 		$292K Buy
+16,828
New +$338K ﹤0.01% 680

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quadrature Capital's NGNE Position: Q4 2025 in Review

Quadrature Capital sold out of Neurogene (NGNE) in Q4 2025, closing a stake of 16,828 shares — an estimated $292K sold.

Quadrature Capital first reported a position in NGNE in Q3 2025 and held it in 1 quarter. The position peaked at $292K in Q3 2025. 93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

  • Quadrature Capital reported no remaining Neurogene position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 16,828 Neurogene shares in Q4 2025, an estimated $292K.
  • Quadrature Capital first reported a position in Neurogene in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Neurogene position peaked at $292K in Q3 2025.
  • 93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.